RxDoctor Payments Data

Dragan Petakov, MD

Internal Medicine · Lowell, MANPI 1629030622

Payments from drug & device makers

$5,849in general payments, 2019–2025

Across 25 payments — averaging $233.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$4K
  • Boehringer Ingelheim$960
  • GSK$151
  • Paratek Pharmaceuticals, Inc.$120
  • Medtronic$96
  • Bayer$81
  • plus $187 from 8 others

What the payments were for

  • Consulting fees$3,70563%
  • Travel & lodging$95816%
  • Food & beverage$1,18720%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,849 in reported general payments places this provider in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$168,857
Medicare patients
430
Services billed
1,502

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala44$173,674
EliquisApixaban201$123,684
DovatoDolutegravir Sodium/Lamivudine21$65,549
JanuviaSitagliptin Phosphate66$60,084
TrulicityDulaglutide45$47,437
CompleraEmtricita/Rilpivirine/Tenof Df12$42,300
Trelegy ElliptaFluticasone/Umeclidin/Vilanter51$34,196
XareltoRivaroxaban30$27,762
DescovyEmtricitabine/Tenofov Alafenam12$25,055
Abiraterone Acetate11$24,600
Isentress HdRaltegravir Potassium12$22,733
OzempicSemaglutide23$22,652
MounjaroTirzepatide15$19,461
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog28$19,199
Lantus SolostarInsulin Glargine,hum.Rec.Anlog129$16,286

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$123,684201 claims
Johnson & JohnsonComplera, Xarelto$17$70,06242 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$151$49,53489 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$30$24,60011 claims
Novo NordiskOzempic$21$22,65223 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$22$20,52939 claims
Boehringer IngelheimJardiance$960$15,98831 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Lowell

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →